To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess and compare the pharmacokinetics (PK) of
Tiotropium delivered via Breath Actuated Inhaler (BAI) (4.5 mcg/day or 9.0 mcg/day),
SPIRIVA®, HandiHaler®, (18 mcg/day) and Respimat® Soft Mist™ Inhaler (SMI) (5.0 mcg/day)
following repeat dosing for 7 days in subjects with COPD.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries